CN101557829A - 增强向生物系统递送的装置和方法 - Google Patents

增强向生物系统递送的装置和方法 Download PDF

Info

Publication number
CN101557829A
CN101557829A CNA2007800425762A CN200780042576A CN101557829A CN 101557829 A CN101557829 A CN 101557829A CN A2007800425762 A CNA2007800425762 A CN A2007800425762A CN 200780042576 A CN200780042576 A CN 200780042576A CN 101557829 A CN101557829 A CN 101557829A
Authority
CN
China
Prior art keywords
guanidine radicals
peg
group
acid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800425762A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·博蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN101557829A publication Critical patent/CN101557829A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800425762A 2006-09-27 2007-09-26 增强向生物系统递送的装置和方法 Pending CN101557829A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06020286.8 2006-09-27
EP06020286A EP1905454A1 (en) 2006-09-27 2006-09-27 Formulations comprising cyclic compounds
EP07013218.8 2007-07-05

Publications (1)

Publication Number Publication Date
CN101557829A true CN101557829A (zh) 2009-10-14

Family

ID=37728182

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800425762A Pending CN101557829A (zh) 2006-09-27 2007-09-26 增强向生物系统递送的装置和方法
CN200780043437.1A Expired - Fee Related CN101541346B (zh) 2006-09-27 2007-09-27 包含环状化合物的制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200780043437.1A Expired - Fee Related CN101541346B (zh) 2006-09-27 2007-09-27 包含环状化合物的制剂

Country Status (10)

Country Link
US (1) US8513188B2 (enExample)
EP (2) EP1905454A1 (enExample)
JP (1) JP5335677B2 (enExample)
CN (2) CN101557829A (enExample)
AU (1) AU2007302270B2 (enExample)
BR (1) BRPI0714761B8 (enExample)
CA (1) CA2664568C (enExample)
ES (1) ES2691736T3 (enExample)
IL (1) IL197760A (enExample)
WO (1) WO2008037484A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102863358A (zh) * 2012-09-20 2013-01-09 华中农业大学 具有除草活性的化合物及其制备方法
CN108658264A (zh) * 2018-04-17 2018-10-16 唐山师范学院 多支化聚环氧琥珀酸衍生物阻垢缓蚀剂的制备及其应用方法
CN113527672A (zh) * 2020-03-30 2021-10-22 复旦大学 一种胍基衍生物及其基因递释系统

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
EP2332929A1 (en) * 2009-11-25 2011-06-15 ArisGen SA Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
EP3000811B1 (en) * 2014-09-24 2017-11-08 Friedrich-Alexander-Universität Erlangen-Nürnberg Crown Ether Complexes and Methods for Poducing the Same
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN116178887B (zh) * 2023-02-16 2024-10-29 东华大学 一种可降解快递袋材料及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185788A1 (en) * 2001-12-11 2003-10-02 Rothbard Jonathan B. Guanidinium transport reagents and conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2923787A1 (de) * 1979-06-12 1980-12-18 Max Planck Gesellschaft Verfahren zur selektiven bildung von disulfidbruecken in polypeptiden und die dabei erhaltenen produkte als wirkstoffe enthaltende arzneimittel
US4474753A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
WO1987003473A1 (en) * 1985-12-04 1987-06-18 Dean Hsieh Transdermal delivery of drugs
ES2395096T3 (es) * 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
WO2001021612A1 (en) * 1999-09-20 2001-03-29 Amato Pharmaceutical Products, Ltd. Process for the preparation of cyclic lactic acid oligomers
JP2006232909A (ja) * 2005-02-23 2006-09-07 Tokai Univ 環状オリゴ乳酸

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185788A1 (en) * 2001-12-11 2003-10-02 Rothbard Jonathan B. Guanidinium transport reagents and conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARY A. LINKLETTER, ET AL.: "Solid-phase synthesis of oligopurine deoxynucleic guanidine (DNG) and analysis of binding with DNA oligomers", 《NUCLEIC ACIDS RESEARCH》 *
THAZHA P. PRAKASH，ET AL.: "2’-O-[2-(Guanidinium)ethyl]-Modified Oligonucleotides: Stabilizing Effect on Duplex and Triplex Structures", 《ORGANIC LETTERS》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102863358A (zh) * 2012-09-20 2013-01-09 华中农业大学 具有除草活性的化合物及其制备方法
CN108658264A (zh) * 2018-04-17 2018-10-16 唐山师范学院 多支化聚环氧琥珀酸衍生物阻垢缓蚀剂的制备及其应用方法
CN108658264B (zh) * 2018-04-17 2021-05-25 唐山师范学院 多支化聚环氧琥珀酸衍生物阻垢缓蚀剂的制备及其应用方法
CN113527672A (zh) * 2020-03-30 2021-10-22 复旦大学 一种胍基衍生物及其基因递释系统
CN113527672B (zh) * 2020-03-30 2022-09-20 复旦大学 一种胍基衍生物及其基因递释系统

Also Published As

Publication number Publication date
WO2008037484A2 (en) 2008-04-03
BRPI0714761B8 (pt) 2021-05-25
EP2068934B1 (en) 2018-07-18
AU2007302270B2 (en) 2014-05-29
CA2664568C (en) 2015-11-24
EP2068934B8 (en) 2018-09-05
US20100137188A1 (en) 2010-06-03
BRPI0714761A2 (pt) 2013-07-02
CA2664568A1 (en) 2008-04-03
BRPI0714761B1 (pt) 2021-03-23
AU2007302270A1 (en) 2008-04-03
CN101541346B (zh) 2014-07-02
EP1905454A1 (en) 2008-04-02
IL197760A0 (en) 2009-12-24
EP2068934A2 (en) 2009-06-17
US8513188B2 (en) 2013-08-20
IL197760A (en) 2016-10-31
WO2008037484A3 (en) 2008-12-18
JP2010504934A (ja) 2010-02-18
ES2691736T3 (es) 2018-11-28
JP5335677B2 (ja) 2013-11-06
CN101541346A (zh) 2009-09-23

Similar Documents

Publication Publication Date Title
CN101557829A (zh) 增强向生物系统递送的装置和方法
US20150359899A1 (en) Means and methods of enhancing delivery to biological systems
KR101589582B1 (ko) 생리활성물질의 고분자량 결합체
CN106456804B (zh) 用于分子的跨膜递送的化合物和方法
CN101534643A (zh) 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
JP2022502451A (ja) 核酸送達のための脂質化カチオン性ペプチド化合物を含む脂質ナノ粒子製剤
JP2021533800A (ja) 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用
WO2023026994A1 (ja) ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
CN108472385A (zh) 与钉合或拼接肽缀合的生物活性化合物
CN101534861B (zh) 具有基于位阻酯的生物可降解连接基的聚环氧烷
CN104185478B (zh) 用于靶向递送至表达lfa-1的细胞的整联蛋白拮抗剂缀合物
JP7644105B2 (ja) 核酸治療薬のための腫瘍標的化ポリペプチドナノ粒子送達システム
JP2023504186A (ja) 標的化された核酸送達のためのペプチドドッキング賦形剤
EP2806898B1 (en) Integrin antagonist conjugates for targeted delivery to cells expressing vla-4
EP4424701A1 (en) Cyclic polypeptide carrier for efficient delivery of nucleic acid, and variants thereof
JP2011522523A (ja) 新規核酸移入系
CN1127477C (zh) 用于亲水分子脂质化的方法和组合物
WO1998013007A9 (en) Methods and compositions for lipidization of hydrophilic molecules
TW202434200A (zh) 用於遞送治療劑至脂肪組織之脂質結合物
CN116615246A (zh) 包含单取代的同-二价连接基的多缀合物
JP4456438B2 (ja) オリゴアルギニン脂質
EP4480943A1 (en) New class of lipids for delivering active ingredients into cells
WO2025261376A1 (zh) 肝外递送配体及其缀合物
HK1022897A (en) Methods and compositions for lipidization of hydrophilic molecules

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20091014